Cannabinoid Agonist Pipeline Insight, 2018 - ResearchAndMarkets.com

DUBLIN--()--The "Cannabinoid Agonist -Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

'Cannabinoid Agonist - Pipeline Insight, 2018' report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Cannabinoid Agonist development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

  • Clinical
  • Non-clinical
  • Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Cannabinoid Agonist - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

The report assesses the active Cannabinoid Agonist pipeline products by developmental stage, product type, molecule type, and administration route.

Key Topics Covered:

1. Report Introduction

2. Cannabinoid Agonist - Overview

3. Pipeline Therapeutics

  • An Overview of Pipeline Products for Cannabinoid Agonist

4. Comparative Analysis

5. Cannabinoid Agonist Pipeline Products in Clinical Stages

  • Product Description
  • Research and Development
  • Product Development Activities

6. Cannabinoid Agonist Pipeline Products in Non-clinical Stages

  • Product Description
  • Research and Development
  • Product Development Activities

7. Therapeutic Assessment: Active Products

  • Pipeline Assessment by Route of Administration
  • Pipeline Assessment by Stage and Route of Administration
  • Pipeline Assessment by Molecule Type
  • Pipeline Assessment by Stage and Molecule Type

8. Inactive Pipeline Products

  • Product Description
  • Research and Development
  • Product Development Activities
  • Reason for dormancy/discontinuation

Companies Mentioned

  • NEOMED
  • Zynerba Pharmaceuticals
  • GW Pharmaceuticals
  • LaraPharm
  • Arena Pharmaceuticals

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/dcl6cm/cannabinoid?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs